{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:47:52Z","timestamp":1791276472419,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ijcard.2012.10.037","type":"journal-article","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T12:18:38Z","timestamp":1353068318000},"page":"1696-1702","source":"Crossref","is-referenced-by-count":34,"title":["Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality"],"prefix":"10.1016","volume":"167","author":[{"given":"Soo","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Kon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2012.10.037_bb0005","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0015","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.97.15.1446","article-title":"Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial","volume":"97","author":"Sacks","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0020","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1001\/jama.283.22.2935","article-title":"Statins and risk of coronary heart disease","volume":"283","author":"LaRosa","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0025","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.38849.487546.DE","article-title":"Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study","volume":"332","author":"Manuel","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0030","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1185\/030079908X292029","article-title":"The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"24","author":"Coleman","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2007.12.004","article-title":"Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER","volume":"200","author":"Polisecki","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2146\/ajhp100271","article-title":"Demographic determinants of response to statin medications","volume":"68","author":"Cone","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0045","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2010.10.036","article-title":"Differential metabolic effects of distinct statins","volume":"215","author":"Koh","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijcard.2011.09.002","article-title":"Caveats to aggressive lowering of lipids by specific statins","volume":"154","author":"Koh","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2012.03.127","article-title":"How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol","volume":"166","author":"Lim","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0065","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jacc.2010.01.050","article-title":"Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol","volume":"55","author":"Bayturan","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0070","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0075","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case\u2013control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0080","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.111.088591","article-title":"Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study","volume":"125","author":"Mora","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0085","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0090","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0095","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0100","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.bjp.0702397","article-title":"Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells","volume":"126","author":"Yada","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0014-5793(01)03007-1","article-title":"Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes","volume":"507","author":"Chamberlain","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0110","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1248\/bpb.26.1681","article-title":"Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin","volume":"26","author":"Kanda","year":"2003","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0115","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0120","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1056\/NEJMp1203020","article-title":"Statins: is it really time to reassess benefits and risks?","volume":"366","author":"Goldfine","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0125","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijcard.2011.11.028","article-title":"Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients","volume":"166","author":"Koh","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0140","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0145","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","article-title":"Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative","volume":"172","author":"Culver","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0150","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0155","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2337\/dc07-2199","article-title":"Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients","volume":"31","author":"Koh","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0160","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2008.09.021","article-title":"Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients","volume":"204","author":"Koh","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0165","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.10.053","article-title":"Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients","volume":"55","author":"Koh","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0170","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2010.02.029","article-title":"Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy","volume":"211","author":"Hoenig","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0180","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"357","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0185","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0190","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0195","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0200","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0205","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0210","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCGENETICS.109.898502","article-title":"Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study","volume":"3","author":"Bailey","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0215","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacc.2007.10.017","article-title":"Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study","volume":"51","author":"Iakoubova","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0220","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/CIRCULATIONAHA.108.773267","article-title":"Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin","volume":"118","author":"Medina","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0225","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1158\/1940-6207.CAPR-10-0007","article-title":"Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer","volume":"3","author":"Lipkin","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0230","first-page":"331","article-title":"Human hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and statin sensitivity","volume":"47","author":"Jawaid","year":"2010","journal-title":"Indian J Biochem Biophys"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0235","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.jacc.2011.02.015","article-title":"No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the Heart Protection Study","volume":"57","author":"Hopewell","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0240","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/dmdi.2011.107","article-title":"Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events","volume":"26","author":"Hubacek","year":"2011","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0250","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3233\/JAD-2010-1319","article-title":"Statin users without an APOE-epsilon4 allele have increased insulin resistance","volume":"19","author":"VanFossen","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0255","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2337\/dc09-1724","article-title":"Association of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects","volume":"33","author":"Takahashi","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0260","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/FPC.0b013e3283023fb2","article-title":"Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant","volume":"18","author":"Peters","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0270","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0275","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17425251003713519","article-title":"Efflux and uptake transporters as determinants of statin response","volume":"6","author":"Rodrigues","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0280","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clpt.2006.09.010","article-title":"Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart","volume":"80","author":"Grube","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0285","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s11095-010-0216-5","article-title":"Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide","volume":"27","author":"Shirasaka","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0290","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4070\/kcj.2003.33.11.1053","article-title":"Effects of simvastatin alone or combined with ramipril on nitric oxide bioactivity and inflammation markers in hypercholesterolemic patients","volume":"33","author":"Son","year":"2003","journal-title":"Korean Circ J"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0295","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1161\/01.CIR.0000143085.86697.13","article-title":"Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients","volume":"110","author":"Koh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0300","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0305","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijcard.2009.03.035","article-title":"The importance of considering alternative or combination strategies for lowering LDL-C","volume":"136","author":"Koh","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0310","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijcard.2008.11.150","article-title":"Targeting converging therapeutic pathways to overcome hypertension","volume":"132","author":"Koh","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2012.10.037_bb0315","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2009.09.007","article-title":"Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction","volume":"209","author":"Koh","year":"2010","journal-title":"Atherosclerosis"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731201412X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731201412X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T09:52:24Z","timestamp":1540115544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752731201412X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S016752731201412X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2012.10.037","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}